Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Uveal Melanoma 2Lymphoma, Large B-Cell, Diffuse 2Neoplasm Metastasis 1Melanoma 1

Interventions

Ipilimumab 10Nivolumab 9Interleukin-2 5Cyclophosphamide 5pembrolizumab 3incomplete Freund's adjuvant 3fludarabine phosphate 3Radiosurgery 3Melphalan 3ADI PEG20 3sotrastaurin 2fludarabine 2Specimen Handling 2Ranibizumab 2Magnetic Resonance Spectroscopy 2MART-1 Antigen 2CTLA-4 Antigen 2Biopsy 2utomilumab 1tocilizumab 1siremadlin 1sargramostim 1ruxolitinib 1relatlimab 1pentetreotide 1obinutuzumab 1montanide ISA 51 1lifileucel 1gp100 Melanoma Antigen 1entinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Uveal Melanoma × sotrastaurin × Clear all
NCT02273219 2023-08-15

Trial of AEB071 in Combination With BYL719 in Patients With Melanoma

Columbia University

Phase 1 Completed
30 enrolled
Dermatologic

Uveal Melanoma, Melanoma

NCT01430416 2020-12-19

Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients

Novartis

Phase 1 Completed
153 enrolled
Dermatologic

Uveal Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡